<DOC>
	<DOCNO>NCT03007225</DOCNO>
	<brief_summary>This study aim compare conventional transarterial chemoembolization ( cTACE ) chemoembolization use doxorubicin drug elute bead ( DEB-TACE ) treatment hepatocellular carcinoma regard short term efficacy safety first 3 month embolization</brief_summary>
	<brief_title>Efficacy Safety Drug Eluting Beads TACE Treatment HCC Egyptian Patients</brief_title>
	<detailed_description>This prospective case control conduct Department Tropical Medicine HCC Clinic , Ain Shams University Hospitals ( Cairo , Egypt ) , The patient divide accord line treatment 2 group : 1 . Group ( I ) : Twenty-five patient underwent Chemoembolization Drug elute bead . 2 . Group ( II ) : Twenty-five patient underwent conventional Chemoembolization ( cTACE ) The total number procedure 77 session ( 37 session TACE bead 40 session conventional TACE ) .Post-procedure follow : Schedule follow : All include patient check : 1 . One week procedure detect early post chemoembolization complication Patients subject Liver function test , Kidney function test , complete blood count Abdominal Ultrasound . 2 . One four month maneuver . Patients subject follow visit : 1 . Complete History take 2 . Thorough clinical examination 3 . Laboratory Investigations include : 1 . Liver function test 2 . Kidney function test 3 . CBC 4 . Serum alpha-fetoprotein . 4 . Triphasic pelvi-abdominal CT Follow imaging perform first fourth month embolization every 3 month thereafter . Repeated embolization schedule `` demand '' basis , residual viable tumor deem unsuitable radiofrequency ablation surgery .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Confirmed diagnosis HCC accord European association study liver diseases Early stage HCC ( Stage A ) , use Barcelona Clinic Liver Cancer ( BCLC ) stag system , ( single 3 nodule &lt; 3cm PS 0 ) whenever curative measure contraindicate BCLC stage B ( intermediate HCC ) . Patent portal vein main branch Informed consent participant enrollment study . Patients Child class C accord Child classification ( BCLC D ) . Patients diffuse HCC ( nonmeasurable lesion ) . Patients thrombosis main portal vein one main branch ( BCLC C ) . Patients extra hepatic invasion . patient refuse participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>